CN101115501A - 涉及脑膜炎球菌外膜囊泡的改进 - Google Patents

涉及脑膜炎球菌外膜囊泡的改进 Download PDF

Info

Publication number
CN101115501A
CN101115501A CNA2005800294697A CN200580029469A CN101115501A CN 101115501 A CN101115501 A CN 101115501A CN A2005800294697 A CNA2005800294697 A CN A2005800294697A CN 200580029469 A CN200580029469 A CN 200580029469A CN 101115501 A CN101115501 A CN 101115501A
Authority
CN
China
Prior art keywords
meningococcal
omv
composition
omvs
serosubtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800294697A
Other languages
English (en)
Chinese (zh)
Inventor
P·奥斯特
M·皮扎
R·拉普奥里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Novartis Vaccines and Diagnostics SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics SRL filed Critical Novartis Vaccines and Diagnostics SRL
Publication of CN101115501A publication Critical patent/CN101115501A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CNA2005800294697A 2004-09-03 2005-09-05 涉及脑膜炎球菌外膜囊泡的改进 Pending CN101115501A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0419627.5A GB0419627D0 (en) 2004-09-03 2004-09-03 Immunogenic bacterial vesicles with outer membrane proteins
GB0419627.5 2004-09-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010169356A Division CN101862451A (zh) 2004-09-03 2005-09-05 涉及脑膜炎球菌外膜囊泡的改进

Publications (1)

Publication Number Publication Date
CN101115501A true CN101115501A (zh) 2008-01-30

Family

ID=33156002

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005800294697A Pending CN101115501A (zh) 2004-09-03 2005-09-05 涉及脑膜炎球菌外膜囊泡的改进
CN201010169356A Pending CN101862451A (zh) 2004-09-03 2005-09-05 涉及脑膜炎球菌外膜囊泡的改进

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201010169356A Pending CN101862451A (zh) 2004-09-03 2005-09-05 涉及脑膜炎球菌外膜囊泡的改进

Country Status (13)

Country Link
US (1) US8808711B2 (enExample)
EP (1) EP1784213B1 (enExample)
JP (2) JP2008511608A (enExample)
CN (2) CN101115501A (enExample)
AU (1) AU2005278896B2 (enExample)
BR (1) BRPI0514883A (enExample)
CA (1) CA2578588A1 (enExample)
ES (1) ES2527859T3 (enExample)
GB (1) GB0419627D0 (enExample)
MX (1) MX2007002633A (enExample)
NZ (1) NZ553521A (enExample)
RU (1) RU2420312C2 (enExample)
WO (1) WO2006024946A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999562A (zh) * 2014-10-29 2017-08-01 仁荷大学校产学协力团 针对恙虫病的免疫组合物及其制备方法

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
EP1860191A3 (en) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
CA2646993C (en) 2006-03-22 2016-01-26 Novartis Ag Regimens for immunisation with meningococcal conjugates
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
US9387239B2 (en) * 2008-05-30 2016-07-12 U.S. Army Medical Research And Materiel Command Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB0822634D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
BRPI0923006A2 (pt) 2008-12-17 2016-03-08 Novartis Ag vacinas meningococicas incluindo receptor de hemoglobina
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
JP5848748B2 (ja) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
EP2833911A4 (en) 2012-04-06 2016-07-13 Univ Cornell SUB-VACCINE VACCINATING PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
US20160120818A1 (en) 2013-02-07 2016-05-05 Glaxosmithline Biological Sa Pharmaceutical compositions comprising vesicles
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
EA201692552A1 (ru) 2014-07-17 2017-06-30 Глаксосмитклайн Байолоджикалс С.А. МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
AR101225A1 (es) 2014-07-17 2016-11-30 Glaxosmithkline Biologicals Sa Vacunas de meningococos
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
AR113011A1 (es) 2017-09-08 2020-01-15 Evelo Biosciences Inc Vesículas extracelulares bacterianas
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
ES2145072T3 (es) * 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
ES2128055T3 (es) * 1994-04-20 1999-05-01 Us Army Vacuna contra infecciones de bacterias gram-negativas.
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
AU748973B2 (en) * 1997-07-17 2002-06-13 Baxter Healthcare Sa Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ES2519440T3 (es) * 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
WO2003009869A1 (en) * 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
DK2255826T3 (en) 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004054611A1 (en) * 2002-12-16 2004-07-01 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
US7031284B2 (en) * 2003-03-03 2006-04-18 Interdigital Technology Corporation Wireless communication method and apparatus for optimizing multi-user detection
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7628995B2 (en) 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
US20090246224A1 (en) * 2006-06-12 2009-10-01 Nathalie Devos Vaccine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999562A (zh) * 2014-10-29 2017-08-01 仁荷大学校产学协力团 针对恙虫病的免疫组合物及其制备方法

Also Published As

Publication number Publication date
NZ553521A (en) 2010-01-29
EP1784213A2 (en) 2007-05-16
US8808711B2 (en) 2014-08-19
WO2006024946A3 (en) 2006-11-30
AU2005278896B2 (en) 2011-12-22
GB0419627D0 (en) 2004-10-06
RU2420312C2 (ru) 2011-06-10
ES2527859T3 (es) 2015-01-30
US20080063665A1 (en) 2008-03-13
CA2578588A1 (en) 2006-03-09
MX2007002633A (es) 2007-05-15
JP2008511608A (ja) 2008-04-17
AU2005278896A1 (en) 2006-03-09
CN101862451A (zh) 2010-10-20
EP1784213B1 (en) 2014-10-29
BRPI0514883A (pt) 2008-06-24
WO2006024946A2 (en) 2006-03-09
RU2007111838A (ru) 2008-10-10
JP2011236254A (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
US8808711B2 (en) Meningococcal outer membrane vesicles
ES2507499T3 (es) Vesículas bacterianas inmunogénicas con proteínas de membrana externa
RU2475496C2 (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
US20130022633A1 (en) MENINGOCOCCAL fHBP POLYPEPTIDES
US20110262484A1 (en) Outer membrane vesicle prime-protein boost vaccine
EP1945249A2 (en) Compositions with antigens adsorbed to calcium phosphate
ES2727798T3 (es) Polipéptidos de FHPP meningocócicos
AU2016273825A1 (en) Modified meningococcal fHBP polypeptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080130